Amy Fontenot
Family · Ville Platte, LANPI 1427365105
Payments from drug & device makers
Across 124 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$247
- Sumitomo Pharma America, Inc.$227
- AstraZeneca$223
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$192
- AbbVie$165
- Amgen$124
- plus $976 from 25 others
What the payments were for
- Food & beverage$2,154100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $247 |
| Sumitomo Pharma America, Inc. | 22 | $227 |
| AstraZeneca | 10 | $223 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $192 |
| AbbVie | 9 | $165 |
| Amgen | 2 | $124 |
| GSK | 5 | $98 |
| Pfizer | 6 | $93 |
| Bayer | 4 | $67 |
| Ardelyx, Inc. | 3 | $64 |
| Cardiovascular Systems Inc. | 1 | $61 |
| Lilly USA, LLC | 4 | $60 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| Merck | 3 | $51 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Novartis | 2 | $37 |
| Lundbeck LLC | 2 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 3 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| United Therapeutics Corporation | 1 | $22 |
| Gilead | 1 | $20 |
| Abbott | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Convatec Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$105
How this compares
$2,154 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $292,494 |
| OzempicSemaglutide | 163 | $162,843 |
| MounjaroTirzepatide | 135 | $156,395 |
| EliquisApixaban | 175 | $115,098 |
| LinzessLinaclotide | 141 | $75,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $65,659 |
| JardianceEmpagliflozin | 75 | $53,665 |
| TrulicityDulaglutide | 50 | $49,852 |
| JanuviaSitagliptin Phosphate | 67 | $42,178 |
| EntrestoSacubitril/Valsartan | 36 | $38,447 |
| FarxigaDapagliflozin Propanediol | 40 | $32,201 |
| MyrbetriqMirabegron | 32 | $17,120 |
| Spiriva RespimatTiotropium Bromide | 24 | $12,651 |
| XareltoRivaroxaban | 21 | $11,689 |
| TrulancePlecanatide | 18 | $10,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $41 | $292,49424 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25 | $60 | $208,406203 claims |
| Novo NordiskOzempic | $247 | $162,843163 claims |
| PfizerEliquis, Premarin | $93 | $122,240195 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta | $98 | $78,340128 claims |
| AbbVieLinzess | $165 | $75,139141 claims |
| MerckJanuvia | $51 | $42,17867 claims |
| NovartisEntresto | $37 | $38,44736 claims |
| AstraZenecaFarxiga | $223 | $32,20140 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $17,12032 claims |
| Johnson & JohnsonXarelto | $13 | $11,68921 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $192 | $10,11018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Ville Platte
- Brittany MillerVille Platte$158K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.